Omalizumab
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Omalizumab: From Severe Allergic Asthma to Bronchitis
One-Sentence Summary
Omalizumab is a recombinant humanised anti-IgE monoclonal antibody, most widely used to treat moderate-to-severe persistent allergic asthma and chronic spontaneous urticaria. The TxGNN model predicts it may also be effective for bronchitis (specifically eosinophilic bronchitis), with 2 clinical trials and 8 publications currently identified in support of this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Severe allergic (IgE-mediated) asthma — not yet populated in this evidence pack’s regulatory dataset; see Data Gaps |
| Predicted New Indication | Bronchitis (eosinophilic bronchitis) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| UK Market Status | Not marketed (per this evidence pack — regulatory dossier collection pending) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (flagged as data gap DG002). Based on well-established pharmacological knowledge, omalizumab is a humanised monoclonal antibody that binds the constant (Cε3) region of circulating IgE, preventing it from binding to the high-affinity FcεRI receptor on mast cells and basophils. This reduces free serum IgE, downregulates FcεRI expression, and dampens the downstream allergic inflammatory cascade — effects that translate clinically into reduced airway inflammation.
Allergic asthma and eosinophilic bronchitis share substantial pathophysiological overlap: both are Type-2/eosinophil-driven airway inflammatory conditions, often distinguished mainly by the absence of airflow obstruction/hyperresponsiveness in eosinophilic bronchitis. Because omalizumab’s mechanism targets the IgE-mediated inflammatory pathway rather than airway smooth muscle or obstruction per se, it is mechanistically plausible that it could benefit patients with eosinophilic bronchitis who share the same underlying immunological driver.
This is further supported by literature identified in the evidence pack — including reviews on omalizumab’s post-approval experience and its relevance to smoking-induced and COPD-overlap airway disease — which reflect ongoing clinical interest in extending anti-IgE therapy beyond classic allergic asthma into related airway inflammatory phenotypes.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT02049294 | Phase 2/3 | Completed | 11 | Randomised, double-blind, placebo-controlled, 3-centre trial testing whether adding omalizumab allows a reduction in prednisone dose in patients with asthma and persistent eosinophilic bronchitis, while maintaining sputum eosinophils <3%. |
| NCT02477332 | Phase 2 | Completed | 382 | Dose-finding study of an anti-IgE antibody (QGE031) as add-on therapy in chronic spontaneous urticaria (CSU); relevance to bronchitis specifically is indirect and should be interpreted with caution. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30196731 | 2018 | Review | Expert Opinion on Pharmacotherapy | Discusses smoking-induced airway diseases (chronic bronchitis, emphysema, asthma-COPD overlap) and treatment challenges, including biologics, in symptomatic smokers with asthma. |
| 35369622 | 2022 | Clinical study | Postepy Dermatologii i Alergologii | Reports use of omalizumab in middle-aged/older patients with severe allergic asthma-COPD overlap phenotype. |
| 16222080 | 2005 | Review | Clinical Reviews in Allergy & Immunology | Reviews omalizumab’s approval and post-approval clinical experience, including reduced airway inflammation and clinical improvement in persistent asthma. |
| 21121874 | 2011 | Pooled safety analysis | Current Medical Research and Opinion | Pooled analysis assessing safety and tolerability of omalizumab in children with IgE-mediated asthma. |
| 26466493 | 2015 | Review | Masui (Japanese J. Anesthesiology) | Reviews perioperative management of patients with bronchial asthma or chronic bronchitis, noting omalizumab’s role in severe allergic disease. |
| 21163396 | 2010 | Review | Revue des Maladies Respiratoires | French expert review on definition, pathophysiology and treatment of adult asthma exacerbations. |
| 17663923 | 2007 | Review | Allergologia et Immunopathologia | Broad review of monoclonal antibody use in paediatrics, including anti-IgE therapy for allergic disease. |
| 31478531 | 2019 | Case report | Journal of Investigational Allergology & Clinical Immunology | Case report of plastic bronchitis following bronchial thermoplasty (asthma-related airway procedure); limited direct relevance to omalizumab efficacy. |
UK Market Information
No UK marketing authorisation records are included in this evidence pack (total_licenses = 0). Regulatory dossier collection for this product has not yet been completed — see Data Gaps below. Note: omalizumab (Xolair®) is a well-established biologic in UK clinical practice for severe allergic asthma and chronic spontaneous urticaria; this section reflects only the data currently captured in this pack, not the drug’s real-world UK availability.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications and drug–drug interaction data are not yet populated in this evidence pack. This is recorded as a blocking data gap (DG001 — TFDA/MHRA label warnings and contraindications), which currently prevents completion of the S1 initial safety assessment for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for the bronchitis indication currently rests on one small completed Phase 2/3 trial (n=11) in eosinophilic bronchitis plus supportive but largely indirect literature. More importantly, essential safety data (SmPC-level warnings and contraindications) required for the S1 safety screen is a blocking data gap, so this candidate cannot yet proceed to formal safety evaluation.
To proceed, the following is needed:
- SmPC-level warnings and contraindications for omalizumab (DG001, blocking — required before S1 safety review)
- Confirmed mechanism of action documentation from DrugBank/SmPC (DG002)
- UK marketing authorisation and licensing records for omalizumab
- Larger, adequately powered controlled trials specifically in eosinophilic/allergic bronchitis populations, beyond the single n=11 pilot study
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.